Rivastigmin ІC (rivastigmine) capsules 1.5 mg. №30

$10.00

Symptomatic treatment of mild to moderate dementia due to Alzheimer’s disease. Symptomatic treatment of mild to moderate dementia in patients with idiopathic Parkinson’s disease.

Category:

Description

Composition and form of release Rivastigmin ІC
The main active ingredient is rivastigmine in the form of hydrotartrate.
The drug is marketed in an encapsulated form, at a dosage according to:

  • 1.5 mg rivastigmine;
  • 3 mg rivastigmine.

Pharmacological properties
This drug is one of the psychoanaleptic drugs used to treat dementia (senile dementia).
The main active ingredient is rivastigmine. The specified pharmaceutical component, when used appropriately, has the ability to reduce the intensity of manifestations of dementia. Rivastigmine is a cholinesterase enzyme inhibitor. Its use promotes the transmission of cholinergic nerve pathways, while inhibiting the degradation of acetylcholines, which are released from cholinergic neurons, which are characterized by intact function. As a consequence, the use of rivastigmine helps to alleviate the lack of cognitive functions of the brain, which is caused by disorders of cholinergic transmission of nerve impulses, in the case of dementia, which is caused by parkinsonism or Alzheimer’s syndrome.
Rivastigmine interacts with target enzymes, forming a covalent complex that briefly inactivates the enzymes.
The effect of the drug is dose-dependent.

Indications Rivastigmin ІC
The specified pharmaceutical agent is used for the symptomatic treatment of mild to moderate dementia caused by Alzheimer’s disease.
Also used for the symptomatic treatment of dementia in patients with idiopathic Parkinson’s disease (mild to moderate).

Contraindications
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Reception is contraindicated in case of severe liver dysfunctions.
Caution should be exercised if anesthesia is required during treatment with rivastigmine. this substance enhances the effect of muscle relaxants.
Also, it should not be used simultaneously with other cholinomimetics, anticholinergic drugs.
It is important to exercise caution when used concomitantly with beta-blockers, antipsychotic drugs.
Not used in pediatrics.

Application during pregnancy and lactation
The drug should not be administered during pregnancy.
If there is a need to use this drug during lactation, then breastfeeding should be suspended for this period.

Method of administration and dosage
Rivastigmin ІC is administered orally with water without chewing. Treatment begins exclusively under the supervision of an experienced attending physician and with constant monitoring of the patient’s well-being and care.
The recommended dosage is 1 tablet 2 times a day, morning and evening, with food.
Start with a minimum dose of 1.5 mg rivastigmine. If tolerance is good, then the dose can be increased to 3 mg rivastigmine per dose. All subsequent dosage increases should be based on drug tolerance levels.
The maximum dosage is 6 mg rivastigmine 2 times a day. The maximum duration of treatment is 6 months. The maintenance dosage is 3 to 6 mg of rivastigmine per dose.
If after 3 months there is no improvement in the condition, treatment with this drug should be discontinued.
Correction of dosage and duration of treatment is determined individually by the attending physician.

Overdose
Overdose can cause:

  • miosis, hot flashes;
  • digestive disorders;
  • bradycardia, bronchospasm;
  • lacrimation, hypotension;
  • tremors, hallucinations, malaise.

Gastric lavage is recommended, in case of severe overdose – atropine.

Side effects
The drug is usually well tolerated. At the same time, side effects may occur during treatment with this drug. In particular:

  • nausea, diarrhea, vomiting, dyspepsia, itching, allergic urticaria, other manifestations of allergic reactions;
  • agitation, nightmares, anxiety, aggression;
  • depression, insomnia;
  • angina pectoris, arrhythmia;
  • stomach ulcer, 12-person intestine, pancreatitis;
  • decreased appetite, hepatitis;
  • asthenia, fatigue, tremor, dystonia;
  • sweating, anorexia, dehydration.

Storage conditions and periods
The shelf life is no more than 2 years.
Storage temperature should not exceed 25 ° C.